Headache
Also known as: Tenderness, Sore
Methodology & AI Transparency ⓘ
Headache Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Almost everyone has had a headache.
- 2 Real-world patient consensus: Mapped to Migraine & Headache Disorders under ICD-10-CM R51.9 for Headache clinical workups.
- 3 Typical cash cost range: Differential triage of Headache (R51.9) utilizes preventive threshold assessment in Headache (R51.9: (>= 4 monthly).
- 4 Top reported side effects / signs: Objective lab/clinical target for Headache: RBC Magnesium & in Headache (R51.9: Riboflavin Status) (RBC Mg 5.0 – 6.4 mg/dL (R51.9)) and Monthly Headache Days in Headache (R51.9: (MHD)).
Ask our AI Specialists anything about Headache
What Is Headache?
Almost everyone has had a headache. Headache is the most common form of pain. It's a major reason people miss days at work or school or visit the doctor. The most common type of headache is a tension headache. Tension headaches are due to tight muscles in your shoulders, neck, scalp and jaw. They are often related to stress, depression or anxiety. You are more likely to get tension headaches if you work too much, don't get enough sleep, miss meals, or use alcohol. Other common types of headaches include migraines , cluster headaches, and sinus headaches. Most people can feel much better by making lifestyle changes, learning ways to relax and taking pain relievers .
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Headache (ICD-10 R51.9) is driven by calcitonin gene-related peptide in Headache (R51.9: (CGRP) neuropeptide release); Cross-referenced with NIH MeSH (Headache, Headache Disorders), specialists in Migraine & Headache Disorders monitor Monthly Headache Days in Headache (R51.9: (MHD)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Headache (R51.9): visual aura [Headache R51.9]
- • Secondary Headache clinical sign: nausea, gastric stasis, in Headache (R51.9: or worsening pain)
- • Symptom flares in Headache correlating with RBC Magnesium & in Headache (R51.9: Riboflavin Status) deviation outside RBC Mg 5.0 – 6.4 mg/dL (R51.9)
- • Functional migraine & headache impact requiring preventive threshold assessment in Headache (R51.9: (>= 4 monthly) evaluation (R51.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Headache Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R51.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Migraine & Headache Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: RBC Magnesium & in Headache (R51.9: Riboflavin Status) | RBC Mg 5.0 – 6.4 mg/dL (R51.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Monthly Headache Days in Headache (R51.9: (MHD)) | < 2 days/month on prevention (R51.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MIDAS Disability Score [Headache R51.9] | Grade I (0 – 5) (R51.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Headache
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Buffered Aspirin, Effervescent Tablet Alka-Seltzer Original Flavor • RxCUI 2606079 | Nonsteroidal Anti-inflammatory Drug | 92% | $0.0200 | $ 9.31 /mo |
| Acetaminophen and Ibuprofen (Nsaid) Acetaminophen 250 Mg and Ibuprofen 125 Mg, Dual Action Pain Reliever • RxCUI RXN-118221131-2125 | Nonsteroidal Anti-inflammatory Drug | 79% | $0.0839 | $ 11.90 /mo |
| Acetaminophen and Asprin Goodys Back and Body Pain • RxCUI 763111 | Nonsteroidal Anti-inflammatory Drug | 83% | $0.0194 | $ 9.29 /mo |
| Acetaminophen, Aspirin, Caffeine Handy Solutions Headache Pain Relief, Medique Pain Off • RxCUI 308297 | Nonsteroidal Anti-inflammatory Drug | 83% | $0.0633 | $ 11.06 /mo |
| Allergy Plus Headache Relief (Acetaminophen, Diphenhydramine HCl) Allergy Plus Headache Relief • RxCUI 2729789 | Histamine-1 Receptor Antagonist | 94% | $0.0194 | $ 9.90 /mo |
| Aspirin Drug Mart Effervescent Pain Relief, Wispirin • RxCUI 198467 | Nonsteroidal Anti-inflammatory Drug | 82% | $0.0253 | $ 5.98 /mo |
| Acetaminophen 250 Mg and Ibuprofen 125 Mg Tablets Acetaminophen 250 Mg and Ibuprofen 125 Mg Tablets Generic • RxCUI RXN-516724258-2169 | Nonsteroidal Anti-inflammatory Drug | 81% | $0.0934 | $ 12.28 /mo |
| Acetaminophen, Ibuprofen Dual Action, Dual Back Pain Reliever • RxCUI 2387532 | Nonsteroidal Anti-inflammatory Drug | 75% | $0.0925 | $ 12.25 /mo |
| Ibuprofen Tablet, Film-Coated Ibuprofen, Caseys 4good • RxCUI RXN-667159819-2220 | Nonsteroidal Anti-inflammatory Drug | 94% | $0.0345 | $ 9.90 /mo |
| Acetaminophen 250 Mg, Aspirin 250 Mg, and Caffeine 65 Mg Acetaminophen 250 Mg, Aspirin 250 Mg, and Caffeine 65 Mg Generic • RxCUI RXN-85786105-2199 | Nonsteroidal Anti-inflammatory Drug | 74% | $0.0194 | $ 9.29 /mo |
| Sinus Plus Headache (Acetaminophen and Phenylephrine Hydrochloride) Sinus Plus Headache • RxCUI 1046378-B68998323 | alpha-1 Adrenergic Agonist | 86% | $0.0800 | $ 14.26 /mo |
| Ibuprofen 200mg Physicians Care Ibuprofen • RxCUI 310965 | Nonsteroidal Anti-inflammatory Drug | 83% | $0.0345 | $ 9.90 /mo |
| Tension Headache Relief (Acetaminophen, Caffeine) Tension Headache Relief • RxCUI 307686 | Central Nervous System Stimulant | 93% | $0.0564 | $ 12.56 /mo |
| Aspirin and Caffeine Quality Choice Pain Relief Powder, Stanback • RxCUI 994435 | Central Nervous System Stimulant | 83% | $0.0158 | $ 9.14 /mo |
| Acetaminophen 250mg Aspirin 250mg Caffeine 65mg Acetaminophen 250mg Aspirin 250mg Caffeine 65mg Generic • RxCUI RXN-69842592-2156 | Nonsteroidal Anti-inflammatory Drug | 86% | $0.0194 | $ 9.29 /mo |
| Alka-Seltzer Original Flavor Alka-Seltzer Original Flavor Generic • RxCUI RXN-67751219-2153 | Nonsteroidal Anti-inflammatory Drug | 92% | $1.4500 | $ 67.22 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Headache)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Reductions in acute medication use and healthcare resource utilization in: What a 1,113-Participant Study Found Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU. Journal of medical economics • 2022-01-15 • Phase III Randomized Trial | N = 1,113 | 96/100 | PMID 35971655 ↗ |
| New Insights on Eptinezumab improved patient-reported outcomes in patients with migraine and: What a 1,072-Participant Study Found This subgroup analysis in patients with CM/MOH at baseline suggests that eptinezumab treatment is associated with early, sustained, and clinically meaningful improvements in patient-reported outcomes. Headache • 2023-02-15 • Phase III Randomized Trial | N = 1,072 | 96/100 | PMID 36633219 ↗ |
| New Insights on Shift from chronic to episodic migraine frequency in a long-term phase 3 study of: What a 558-Participant Study Found These results suggest that galcanezumab helped a majority of patients convert from chronic to episodic migraine frequency over the course of this 12-month study. The journal of headache and pain • 2025-02-03 • Phase III Randomized Trial | N = 558 | 93/100 | PMID 39901101 ↗ |
| New Insights on Tolerability and safety of galcanezumab in patients with chronic cluster headache: What a 233-Participant Study Found Galcanezumab 300 mg monthly had a favorable tolerability and safety profile in patients with chronic CH with up to 15 months of treatment. Headache • 2022-01-15 • Phase III Randomized Trial | N = 233 | 88/100 | PMID 34806783 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical efficacy of escitalopram combined with botulinum toxin A in patients The combination of escitalopram with BoNT/A is a significantly effective intervention in improving clinical efficacy and reducing the recurrence in patients with GAD and comorbid headache, and we believe that this approach... Psychopharmacology • 2023-10-15 • Randomized Controlled Trial | N = 101 | 88/100 | PMID 37481677 ↗ |
Headache Patient Community & “People Like Me” Threads
Filter Headache community threads and patient logs by age, biological sex, dosage, and treatment duration.